Search Results - "Sender, Lennie"

Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge by Gabitzsch, Elizabeth, Safrit, Jeffrey T., Verma, Mohit, Rice, Adrian, Sieling, Peter, Zakin, Lise, Shin, Annie, Morimoto, Brett, Adisetiyo, Helty, Wong, Raymond, Bezawada, Ashish, Dinkins, Kyle, Balint, Joseph, Peykov, Victor, Garban, Hermes, Liu, Philip, Bacon, Andrew, Bone, Pete, Drew, Jeff, Sanford, Daniel C., Spilman, Patricia, Sender, Lennie, Rabizadeh, Shahrooz, Niazi, Kayvan, Soon-Shiong, Patrick

“…We have developed a dual-antigen COVID-19 vaccine incorporating genes for a modified SARS-CoV-2 spike protein (S-Fusion) and the viral nucleocapsid (N) protein…”
Get full text

358 Characterization of the anti-tumor activity of memory cytokine enriched NK cells against tumors with neuroendocrine features by Fousek, Kristen, Horn, Lucas A, Qin, Haiyan, Angstadt, Shantel, Saxena, Manju, Sender, Lennie, Soon-Shiong, Patrick, Schlom, Jeffrey, Palena, Claudia

“…BackgroundSmall cell lung cancer (SCLC) is an aggressive neuroendocrine (NE) carcinoma with few treatment options. Although immune checkpoint blockade (ICB) is…”
Get full text

710 Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist) by Fousek, Kristen, Horn, Lucas, Qin, Haiyan, Reddy, Bobby, Sender, Lennie, Shiong, Patrick Soon, Schlom, Jeffrey, Palena, Claudia

“…BackgroundSmall cell lung cancer (SCLC) is a highly aggressive tumor with a 5-year survival rate of less than 5%. Traditionally characterized as a…”
Get full text

Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate by Moini, Katayoun, Seery, Tara, Nangia, Chaitali, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Spilman, Patricia, Sender, Lennie, Soon-Shiong, Patrick

“…Multimodal temporal therapy orchestrated to leverage immunotherapy, tumor-targeted chemotherapy, and natural killer (NK) cell therapy may provide an…”
Get full text

Abstract P5-04-02: Safety and efficacy from first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK) in patients with 2nd-line or greater metastatic triple-negative breast cancer (TNBC) by Kistler, Mira, Nangia, Chaitali, To, Christina, Sender, Lennie, Lee, John, Jones, Frank, Jafari, Omid, Seery, Tara, Rabizadeh, Shahrooz, Niazi, Kayvan, Rock, Amy, Soon-Shiong, Patrick

“…TNBC is an aggressive subtype of breast cancer with limited treatment options. We hypothesize that effective response against TNBC requires a coordinated…”
Get full text

Quality of Life in the Phase 2/3 Trial of N-803 Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer by Chamie, Karim, Chang, Sam S, Kramolowsky, Eugene V, Gonzalgo, Mark L, Huang, Megan, Bhar, Paul, Spilman, Patricia, Sender, Lennie, Reddy, Sandeep K, Soon-Shiong, Patrick

“…In the phase 2/3 study QUILT 3.032 (NCT03022825), the ability of the IL-15RαFc superagonist N-803 (nogapendekin alfa inbakicept or NAI) plus bacillus…”
Get full text

Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer by Chamie, Karim, Chang, Sam S, Kramolowsky, Eugene V, Gonzalgo, Mark L, Huang, Megan, Bhar, Paul, Spilman, Patricia, Sender, Lennie, Reddy, Sandeep K, Soon-Shiong, Patrick

“…INTRODUCTIONIn the phase 2/3 study QUILT-3.032 (NCT03022825), the ability of the IL-15RαFc superagonist N-803 (nogapendekin alfa inbakicept) plus bacillus…”
Get full text